Term Name: enasidenib
Synonyms: 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl]amino}-1,3,5-triazin-2-yl)amino]propan-2-ol, AG 221, AG-221, CC-90007, enasidenib, enasidenibum, Idhifa
Definition: A 1,3,5-triazine which is substituted by (2-hydroxy-2-methylpropyl)nitrilo, 6-(trifluoromethyl)pyridin-2-yl and [2-(trifluoromethyl)pyridin-4-yl]nitrilo groups at positions 2,4 and 6, respectively. It is an isocitrate dehydrogenase-2 (IDH2) inhibitor which has been approved for the treatment of adults with relapsed or refractory acute myeloid leukaemia (AML).
Ontology: ChEBI [CHEBI:145374]  ( EBI )

Relationships
is a type of: 1,3,5-triazines aminopyridine aromatic amine organofluorine compound secondary amino compound tertiary alcohol
has_role: antineoplastic agent EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor